Boyd Watterson Asset Managementoh Lowers stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Boyd Watterson Asset Managementoh reduced its stake in Merck & Co. by 0.69% during the most recent quarter end. The investment management company now holds a total of 51,784 shares of Merck & Co. which is valued at $2,907,154 after selling 360 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Apr 15, 2016.Merck & Co. makes up approximately 1.44% of Boyd Watterson Asset Managementoh’s portfolio.

Merck & Co. opened for trading at $56.34 and hit $57.03 on the upside on Wednesday, eventually ending the session at $56.6, with a gain of 0.04% or 0.02 points. The heightened volatility saw the trading volume jump to 1,05,35,254 shares. Company has a market cap of $157,080 M.

Other Hedge Funds, Including , First Hawaiian Bank reduced its stake in MRK by selling 17 shares or 0.27% in the most recent quarter. The Hedge Fund company now holds 6,238 shares of MRK which is valued at $350,201. Merck & Co. makes up approx 0.06% of First Hawaiian Bank’s portfolio.Lynch Associatesin reduced its stake in MRK by selling 1,790 shares or 2.7% in the most recent quarter. The Hedge Fund company now holds 64,414 shares of MRK which is valued at $3,616,202. Merck & Co. makes up approx 1.70% of Lynch Associatesin’s portfolio.First Premier Bank boosted its stake in MRK in the latest quarter, The investment management firm added 665 additional shares and now holds a total of 16,587 shares of Merck & Co. which is valued at $913,114. Merck & Co. makes up approx 0.74% of First Premier Bank’s portfolio.First American Bank boosted its stake in MRK in the latest quarter, The investment management firm added 947 additional shares and now holds a total of 89,371 shares of Merck & Co. which is valued at $4,919,874. Merck & Co. makes up approx 0.51% of First American Bank’s portfolio.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.